Scott Wang

Morgan Stanley analysts David Lewis and Scott Wang reviewed Johnson & Johnson (NYSE: JNJ) after the US patent office rejected its 2018 patent of Remicade. Morgan Stanley currently rates Johnson & Johnson as Equal Weight. Johnson & Johnson is expected to appeal to the Patent Approval...